Home › Stocks › LLY vs ABBV
LLY
Eli Lilly and Company
$1,149.15
vs
ABBV
AbbVie Inc.
$224.95

Head-to-Head Comparison

MetricLLYABBV
Market Cap$750.0B$397.4B
P/E Ratio65.018.0
Div YieldN/AN/A
SectorHealthcareHealthcare
Beta0.520.31
RevenueN/AN/A
Net IncomeN/AN/A
EPSN/AN/A

AI Comparison Brief

AI Generated
Verdict
AbbVie Inc. (ABBV) is the superior investment at this time due to its established market presence with a substantial market cap of $397.44 billion and a lower beta of 0.309, indicating lower volatility. While both companies currently lack P/E and dividend yield data, AbbVie's overall stability and established product portfolio position it better for steady growth and risk management compared to Eli Lilly (LLY), which lacks market capitalization data and is thus harder to evaluate.
Key Differences
  • Business Model: AbbVie has a diversified product lineup, including blockbuster drugs like Humira, which provides a steady revenue stream, while LLY's specific offerings and growth trajectory are not detailed, making it harder to assess its competitive position.
  • Valuation: AbbVie's market cap of $397.44 billion reflects its established market status, whereas LLY's market cap is not available, raising concerns about its valuation and market footprint.
  • Risk Profile: With a beta of 0.309, AbbVie exhibits lower volatility compared to LLY's beta of 0.517, suggesting that ABBV is likely to provide a more stable investment during market fluctuations.
  • Growth Potential: AbbVie’s existing market presence and solid portfolio suggest robust growth potential, whereas LLY's lack of data on earnings and market capitalization creates uncertainty regarding its growth trajectory.
Bottom Line
Investors seeking stability and established growth should favor AbbVie (ABBV) for its strong market position and lower risk profile, while those willing to take on more uncertainty may consider Eli Lilly (LLY) if future data becomes more favorable.
This comparison is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.
Analysis generated 2026-06-16

Price Chart — LLY vs ABBV

Loading chart...
→ Eli Lilly and Company (LLY) Full Analysis → AbbVie Inc. (ABBV) Full Analysis ← Stock Screener
Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms